Literature DB >> 31707529

Prior Relapse, Ongoing Alcohol Consumption, and Failure to Engage in Treatment Predict Alcohol Relapse After Liver Transplantation.

Sasha Deutsch-Link1, Robert M Weinrieb2, Lauren S Jones3, Steven F Solga3, Ethan M Weinberg3, Marina Serper3.   

Abstract

BACKGROUND: Alcohol-related liver disease (ALD) is the leading indication for liver transplantation (LT) in the USA. Alcohol relapse post-LT can negatively impact long-term outcomes, and prognostic scoring systems are available for further study. AIMS: Our study aims were to: (1) evaluate the relationship between alcohol relapse and rejection and mortality, (2) investigate risk factors for relapse, and (3) assess predictive validity of the SIPAT (Stanford Integrated Psychosocial Assessment for Transplant) and SALT (Sustained Alcohol Use Post-Liver Transplant) scores on post-LT alcohol relapse.
METHODS: We conducted a retrospective chart review of 155 patients transplanted for chronic ALD at a single transplant center. Cox proportional hazard models assessed the relationship between alcohol relapse and allograft rejection and psychosocial risk factors for relapse.
RESULTS: 20% of patients met criteria for alcohol relapse. Alcohol relapse was associated with allograft rejection (HR 2.33, 95% CI 1.11-4.91, p = .03). Three variables most strongly associated with alcohol relapse: prior relapse, failure to engage in recommended alcohol treatment, and continued drinking with liver disease, which were combined into a psychosocial model. SIPAT score≥ 21 and SALT score ≥ 7 were associated with alcohol relapse (HR 6.40, 95% CI 1.36-30.18, p = .019 and HR 2.30, 95% CI 1.12-4.75, p = .024). Receiver operator characteristic analysis compared predictive ability of our psychosocial model to SIPAT (C-statistic .83 compared to .71) and SALT (C-statistic = .77 compared to .62).
CONCLUSION: We identified important psychosocial predictors of post-LT alcohol relapse and validated SIPAT and SALT scores as pre-transplant risk factors for alcohol relapse.

Entities:  

Keywords:  Alcohol relapse; Alcoholic; Liver cirrhosis; Liver transplantation; SALT score; SIPAT score

Year:  2019        PMID: 31707529     DOI: 10.1007/s10620-019-05937-4

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  5 in total

1.  Medication non-adherence among liver transplant recipients.

Authors:  Lauren S Jones; Marina Serper
Journal:  Curr Hepatol Rep       Date:  2020-10-24

2.  The Stanford Integrated Psychosocial Assessment for Transplant Is Associated With Outcomes Before and After Liver Transplantation.

Authors:  Sasha Deutsch-Link; Ethan M Weinberg; Therese Bittermann; Mackenzie McDougal; Aniket Dhariwal; Lauren S Jones; Robert M Weinrieb; Arpita G Banerjee; Senayish Addis; Marina Serper
Journal:  Liver Transpl       Date:  2021-05       Impact factor: 6.112

3.  An Assessment of the Psychosocial Evaluation for Early Liver Transplantation in Patients With Acute Alcoholic Hepatitis in the Context of Alcohol Use Disorder, a Case-Control Study.

Authors:  Aryeh Dienstag; Penina Dienstag; Kanwal Mohan; Omar Mirza; Elizabeth Schubert; Laura Ford; Margot Edelman; Gene Im; Akhil Shenoy
Journal:  Subst Abuse       Date:  2022-08-10

4.  Artificial intelligence to identify harmful alcohol use after early liver transplant for alcohol-associated hepatitis.

Authors:  Brian P Lee; Nitzan Roth; Prathik Rao; Gene Y Im; Alexander S Vogel; Johann Hasbun; Yoel Roth; Akhil Shenoy; Antonios Arvelakis; Laura Ford; Inga Dawe; Thomas D Schiano; Jordan P Davis; John P Rice; Sheila Eswaran; Ethan Weinberg; Hyosun Han; Christine Hsu; Oren K Fix; Haripriya Maddur; R Mark Ghobrial; George Therapondos; Bistra Dilkina; Norah A Terrault
Journal:  Am J Transplant       Date:  2022-04-25       Impact factor: 9.369

5.  Identification of Quantifiable Predictors of Relapse in Patients with Alcohol-Associated Liver Disease.

Authors:  Nicole T Shen; Alyson Kaplan; Khalid Fahoum; Elora Basu; Akhil Shenoy; Nabeel Wahid; Amanda Ivatorov; Joseph Pisa; Annaheta Salajegheh; Enad Dawod; Russell Rosenblatt; Brett Fortune; Monika Safford; Robert S Brown
Journal:  Hepatol Commun       Date:  2021-03-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.